Phosphodiesterase‐4 inhibitors for chronic obstructive pulmonary disease

Authors of this review of 42 RCTs (n=24,503) suggest data provide cautious support for the use of PDE₄ inhibitors in COPD. They may have a place as add‐on therapy for a subgroup of people with persistent symptoms or exacerbations despite optimal COPD management.


Cochrane Database of Systematic Reviews